Epstein Secrets

TO ITS STOCKHOLDERS ON A TAX-FREE BASIS IN JULY OR AUGUST IN A SPINOFF TRANSACTION. The Dealer Managers for the Offer are: Lazard Freres & Co. LLC J.P. Morg=n & Co. May 4, 1999 IMPORTANT Any stockholder desiring to accept the Offer should either (1) request his or her broker, dealer, commercial bank, t

that the Off=r be made by a licensed broker or dealer, the Offer shall be deemed to be mad= on behalf of the Company by Lazard Freres & Co. Ilc and J.P. Morgan Sec=rities Inc. or one or more registered brokers or dealers licensed under the laws o= such jurisdiction. 2 Instructions with Respect to Offer to Pur

oo and the proposed spinoff, please refer to the Registration Statement on Form 10 filed by Limited Too with the Securities and Exchange Commission (the "Commission") on=May 4, 1999. The Limited Too spinoff is currently expected to occur in July or August of 1999 and the Galyan's transaction, which is subject t

ale Price"). Payment of the Commission to Sublime shall be made as follows: Bank Name: Bank Address: Account Name: Account Number: ABA Number: Chase Bank 1003 Lexington Avenue, New York, NY 10021 Sublime Art LLC The Commission shall be due and payable to Sublime only if and when Narrows receives the

lee' (on the stretcher) (the "Klee"). Narrows agrees to pay to Sublime the sum of One Million Eight Hundred Thousand Dollars U.S. ($1,800,000.00) (the "Commission") as the Commission for arranging the sale of the Klee to Laura Gowen Art Connection SA (the "Buyer"). The Commission shall be paid by Narrows to S

eement with respect to the Term Loan Credit Agreement, dated as of October 6, 2004, among Limited Brands, Inc., the Lenders party thereto, JPMorgan Chase Bank, as Administrative Agent, and Bank of America, N.A. and Citicorp North America, Inc., as Co-Syndication Agents, incorporated by reference to Exhibit

o Exhibit 4.2 to the Company's Registration Statement on Form S-3 (File no. 33.53366) originally filed with the Securities and Exchange Commission (the "Commission") on October 16, 1992, as amended by Amendment No. I thereto, filed with the Commission on February 23, 1993 (the "1993 Form S-3"). 4.3 Proposed

invested Slim at a valuation of 5204m. Other investors in the round included Kleiner Perkins, Google Ventures, Roche and Labcorp. In September 2013, J.P. Morgan and Goldman Sachs led the IPO of Foundation Medicine. As of 240, January 2014, Foundation Medicine had a market capitalization of 5900m. 23andme 2

rs in Guernsey The Fund is a Cayman Islands exempted limited partnership and has not been authorised by the Guernsey Financial Services Commission (the "Commission") under the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended. Accordingly, any marketing material or prospectus in relation to